Approved indication: Endometrin is FDA‑approved to support embryo implantation and early pregnancy by supplementing corpus luteum function as part of an assisted reproductive technology (ART) treatment program for infertile women.

Off‑label uses: Clinicians may use vaginal progesterone products, including Endometrin, off label for luteal phase support in non‑IVF fertility protocols or certain early‑pregnancy situations (such as threatened miscarriage), but the strength of evidence varies by condition and is generally less robust than for its use in standard IVF/ART cycles.

Efficacy expectations: Progesterone levels are supported soon after insertion, but benefits are seen clinically as normal implantation and ongoing pregnancy, typically evaluated about 2 weeks after embryo transfer; in IVF studies, pregnancy outcomes with Endometrin are generally comparable to those achieved with other vaginal progesterone formulations and intramuscular progesterone when used according to ART protocols.

Typical dosing and how to use: For women undergoing ART, the standard dose is one 100 mg insert placed deep into the vagina two or three times daily using the provided disposable applicator, starting the day after oocyte (egg) retrieval and continuing, if pregnancy occurs, for up to a total of 10 weeks as directed by the fertility clinic.

Administration tips: Wash your hands, place the tablet into the tip of the applicator, gently insert the applicator into the vagina while standing, sitting, or lying down, press the plunger to release the insert, then remove and discard the single‑use applicator; Endometrin should not be used at the same time as other vaginal products (such as creams, suppositories, or antifungals) unless your clinician instructs otherwise.

Special instructions: Use doses at evenly spaced times each day and continue exactly as prescribed even if you feel well; because efficacy in women 35 years and older has been less clearly defined in trials, dosing and duration in this age group are individualized by the fertility specialist.

Missed dose: If you miss a dose, insert it as soon as you remember unless it is almost time for the next scheduled dose, in which case skip the missed dose and resume your regular schedule without using extra inserts to make up for it.

Overdose: Using more inserts than prescribed may increase side effects such as nausea, breast tenderness, or drowsiness; if a large amount is used, or if someone (especially a child) swallows an insert, contact your clinician, a poison control center, or emergency services right away.

Common side effects:

• Common effects include pelvic or post–egg‑retrieval pain, abdominal pain or cramping, nausea, vaginal discharge, and symptoms related to ovarian hyperstimulation; these are usually mild to moderate and occur during the IVF cycle.
• Other possible effects are breast tenderness, bloating, headache, mood changes, and local vaginal irritation or itching, which are typically manageable and improve over time or after treatment ends.

Serious or rare adverse effects:

• Serious blood clots (deep vein thrombosis, pulmonary embolism), stroke, heart attack, or retinal vein thrombosis can occur with progesterone therapy, signaled by sudden chest pain, shortness of breath, severe headache, vision changes, or leg pain and swelling.
• Severe allergic reactions, marked depression or mood changes, jaundice or other signs of liver problems, and heavy or unexplained vaginal bleeding require immediate medical attention and stopping the medication until evaluated.

Warnings and precautions: Endometrin is contraindicated in people with active or past serious blood clots, certain hormone‑dependent cancers (breast or genital), liver disease, undiagnosed vaginal bleeding, or known missed abortion or ectopic pregnancy; it should be used cautiously in those with depression, migraines, asthma, heart or kidney disease, and is intended for reproductive‑age women under specialist supervision, including early pregnancy, not for children or routine use in older adults.

Relative safety: Because Endometrin is given vaginally and acts mainly on the uterus, it tends to cause fewer whole‑body hormone effects than some high‑dose oral or injectable progesterone regimens, but the small risk of serious clotting or liver problems remains, particularly in patients with underlying risk factors.

Side effect reporting and safety updates: Side effects can be reported to the manufacturer (Ferring Pharmaceuticals) or to the FDA MedWatch program by phone at 1‑800‑FDA‑1088 or via the FDA website, where patients and clinicians can also find the latest safety communications and updated prescribing information.

Drug and product interactions:

• Endometrin should generally not be used at the same time as other vaginal products (for example antifungal creams, other suppositories, or vaginal lubricants) unless approved by your fertility specialist, because they can change how progesterone is released and absorbed.
• Medicines that strongly affect liver enzymes (such as certain seizure medicines or rifampin) and herbal supplements like St. John’s wort may reduce progesterone levels, so provide your clinician with a complete list of all prescription drugs, over‑the‑counter medicines, and supplements.
• There are no specific food restrictions, and no direct interaction with alcohol is known, but alcohol is generally discouraged during fertility treatment and pregnancy.

Precautions and conditions needing extra care: Endometrin is contraindicated in people with active or past serious blood clots, certain hormone‑dependent cancers, liver disease, undiagnosed vaginal bleeding, or known missed abortion or ectopic pregnancy, and should be used carefully in those with depression, migraines, asthma, heart disease, or kidney disease under close medical supervision.

Monitoring: During ART cycles, clinicians typically monitor patients with physical exams, ultrasound, and hormone and pregnancy tests; there are no routine blood tests required specifically for Endometrin, but patients should promptly report new headaches, vision changes, chest pain, shortness of breath, leg swelling, severe abdominal pain, or mood changes, and should inform any surgeon or radiology team that they are on progesterone and may be pregnant, even though no specific imaging‑contrast interactions are known.

Q: How is Endometrin used during IVF treatment?
A: Endometrin is usually started the day after egg retrieval and inserted vaginally two or three times a day to keep progesterone levels high enough to support embryo implantation and early pregnancy, typically continuing for up to 10 weeks if pregnancy is confirmed.

Q: How is Endometrin different from progesterone injections?
A: Both provide progesterone support, but Endometrin is a vaginal insert that delivers the hormone near the uterus and avoids injections, while intramuscular progesterone is given as a shot in the muscle; many IVF programs consider them similarly effective when used correctly and choose based on patient and clinic preference.

Q: Is vaginal discharge normal while using Endometrin?
A: Yes, it is common to notice a whitish or clear discharge as the insert base dissolves and some medication or residue comes out of the vagina, but you should contact your clinic if the discharge becomes foul‑smelling, green, or is associated with significant pain or fever.

Q: Can I use tampons or have intercourse while on Endometrin?
A: Tampons are generally discouraged because they can absorb or dislodge the insert, but most clinics allow gentle intercourse unless they have given specific restrictions related to your IVF procedure, so follow your own provider’s instructions.

Q: Is Endometrin safe in early pregnancy?
A: Endometrin is specifically used to support very early pregnancy in ART cycles, and available data have not shown an increase in birth defects when used as directed, though it should always be taken under the guidance of a fertility or obstetric specialist.

Storage: Store Endometrin at room temperature 20–25°C (68–77°F), allow short excursions between 15–30°C (59–86°F), keep each insert in its sealed foil pouch until use, and keep out of the reach of children and away from excess heat, moisture, and direct light.

Disposal: Place used applicators and wrappers in the household trash, and discard unused inserts (in their wrappers) with household waste rather than flushing them; follow any local medication take‑back or pharmacy guidance if available.